Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Erivedge Vismodegib Basal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete
Gazyva Obinutuzumab Chronic Lymphocytic Leukemia Reimburse Complete
Giotrif Afatinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse Complete
Halaven Eribulin Mesylate Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Inlyta Axitinib Metastatic Renal Cell Carcinoma Reimburse Complete
Istodax Romidepsin Peripheral T-Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete
Jakavi Ruxolitinib Myelofibrosis Reimburse with clinical criteria and/or conditions Complete
Kadcyla Trastuzumab emtansine Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Mekinist Trametinib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Nexavar Sorafenib Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) Do not reimburse Complete